Evidence map›Paper›PMID 29767306›Full record

ArticleJournal of neuro-oncology2018

Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.

Maura Massimino, Veronica Biassoni, Rosalba Miceli, Elisabetta Schiavello, Monika Warmuth-Metz, Piergiorgio Modena, Michela Casanova, Emilia Pecori, Felice Giangaspero, Manila Antonelli and 13 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Maura MassiminoPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy. maura.massimino@istitutotumori.mi.it.
Veronica BiassoniPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Rosalba MiceliMedical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.
Elisabetta SchiavelloPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Monika Warmuth-MetzDepartment of Neuroradiology, University of Würzburg, Josef-Schneider-Str.11, 97080, Wurzburg, Germany.
Piergiorgio ModenaGenetics Unit, Pathology Department, Ospedale S. Anna, San Fermo della Battaglia, 22100, Como, Italy.
Michela CasanovaPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Emilia PecoriRadiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.
Felice GiangasperoRadiological and Oncological Sciences Department, Università Sapienza, Viale del Policlinico, 00151, Roma, Italy.
Manila AntonelliRadiological and Oncological Sciences Department, Università Sapienza, Viale del Policlinico, 00151, Roma, Italy.
Francesca Romana ButtarelliPathology Department, Università Sapienza, Viale del Policlinico, 00151, Roma, Italy.
Paolo PotepanRadiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.
Bianca PolloNeuropathology Unit, IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 20133, Milano, Italy.
Raffaele NunziataNeuropathology Unit, IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 20133, Milano, Italy.
Filippo SpreaficoPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Marta PoddaPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Andrea AnichiniHuman Tumor Immunobiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.
Carlo Alfredo ClericiPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, (INT), Via Venezian 1, 20133, Milano, Italy.
Iacopo SardiNeuro-Oncology Unit, Ospedale Meyer, Viale Pieraccini 24, 50139, Firenze, Italy.
Loris De CeccoMolecular Therapies Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.
Udo BodeDepartment of Pediatric Hematology/Oncology, University of Bonn Medical School, Bonn, Germany.
Ferdinand BachOncoscience AG, Hafenstraße 32, 22880, Wedel, Germany.
Lorenza GandolaRadiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic experience reported in the paper was conceived after the use of nimotuzumab and radiotherapy (BSCPED-05 international multicentric trial, EUDRACT 2005-003100-11) in 2009 when we decided to explore the activity of the same combination plus vinorelbine (see the paper for the rationale).

Identifiers

PMID29767306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.